INNODIA Family & Friends Early-Stage T1D Detection Protocol

Launched by INNODIA IVZW · Aug 5, 2025

Keywords

ClinConnect Summary

This clinical trial, called INNODIA DETECT, is looking for people who might be at higher risk of developing Type 1 Diabetes (T1D). T1D is a condition where the body stops making insulin, a hormone that helps turn sugar in the blood into energy. This happens because the immune system mistakenly attacks the cells in the pancreas that produce insulin. The study tests for special markers in the blood, called autoantibodies, which can show if this process has started—even before any symptoms appear. Finding these markers early can help doctors understand who might develop T1D in the future.

If you are between 1 and 45 years old and have a close family member or friend diagnosed with T1D before age 45, you might be able to join this study. Participants will provide a small blood sample to check for these autoantibodies. If no autoantibodies are found, you won’t need further testing and will finish the study. But if one or more autoantibodies are found, the clinical team will contact you to confirm the results with another blood test at the hospital. If confirmed, you may be invited to join a follow-up study to monitor your health over time. This study is currently recruiting participants across Europe and aims to help catch T1D early, so treatment and care can begin sooner if needed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Have given written informed consent to participate
• • 2. Be aged between 1 and 45 years
• • 3. Have a family relative with T1D or close friend diagnosed with symptomatic T1D at age \<45 years
• Exclusion Criteria:
• • 1. Previous diagnosis of stage 3 T1D or other forms of diabetes
• • 2. Unable/unwilling to consent to participation